tiprankstipranks
Neurogene price target lowered to $45 from $60 at BMO Capital
PremiumThe FlyNeurogene price target lowered to $45 from $60 at BMO Capital
1M ago
Neurogene price target lowered to $46 from $72 at Baird
Premium
The Fly
Neurogene price target lowered to $46 from $72 at Baird
1M ago
Neurogene selloff on safety event an overreaction, says H.C. Wainwright
Premium
The Fly
Neurogene selloff on safety event an overreaction, says H.C. Wainwright
1M ago
Neurogene provides update on NGN-401 clinical trial for Rett syndrome
PremiumThe FlyNeurogene provides update on NGN-401 clinical trial for Rett syndrome
1M ago
Neurogene Reports Promising Interim Results for NGN-401 Trial
Premium
Company Announcements
Neurogene Reports Promising Interim Results for NGN-401 Trial
1M ago
Neurogene price target raised to $60 from $44 at Stifel
Premium
The Fly
Neurogene price target raised to $60 from $44 at Stifel
1M ago
Neurogene reports ‘positive’ interim efficacy data from NGN-401 participants
PremiumThe FlyNeurogene reports ‘positive’ interim efficacy data from NGN-401 participants
1M ago
Neurogene Secures $200M for Genetic Therapy Development
Premium
Company Announcements
Neurogene Secures $200M for Genetic Therapy Development
2M ago
Three new option listings and one option delisting on August 14th
Premium
The Fly
Three new option listings and one option delisting on August 14th
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100